Canaccord Genuity Group upgraded shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) to a strong-buy rating in a research note published on Tuesday morning, Zacks.com reports.
A number of other equities analysts have also recently weighed in on LUCD. Canaccord Genuity Group reissued a buy rating and set a $3.00 price target on shares of Lucid Diagnostics in a research report on Tuesday. Cantor Fitzgerald reissued an overweight rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research note on Wednesday, May 15th. Needham & Company LLC reaffirmed a buy rating and set a $2.50 price target on shares of Lucid Diagnostics in a research report on Tuesday. Finally, Ascendiant Capital Markets cut their price objective on Lucid Diagnostics from $8.00 to $7.50 and set a buy rating on the stock in a report on Thursday, June 6th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Buy and a consensus price target of $4.00.
View Our Latest Stock Analysis on Lucid Diagnostics
Lucid Diagnostics Price Performance
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $1.00 million during the quarter. Analysts forecast that Lucid Diagnostics will post -1.06 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Lucid Diagnostics stock. Virtu Financial LLC lifted its holdings in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) by 66.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,671 shares of the company’s stock after purchasing an additional 13,835 shares during the quarter. Virtu Financial LLC owned 0.07% of Lucid Diagnostics worth $28,000 as of its most recent SEC filing. Institutional investors and hedge funds own 74.01% of the company’s stock.
Lucid Diagnostics Company Profile
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
See Also
- Five stocks we like better than Lucid Diagnostics
- How Investors Can Find the Best Cheap Dividend Stocks
- Lockheed Martin’s Sky-High Surge: Buy Now or Wait for a Landing?
- Which Wall Street Analysts are the Most Accurate?
- Deere Rebounds on Earnings Beat, But Uphill Battle Remains
- The Significance of Brokerage Rankings in Stock Selection
- Mutual Funds vs Hedge Funds: What’s the Difference?
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.